Letters
Cardiovascular diseases General medicine Pharmacology
Volume 187 - Issue 6

Guidelines for the management of acute coronary syndromes 2006

Authors:  Mark Little and Chris Johnstone

Med J Aust 2007; 187 (6): 372. || doi: 10.5694/j.1326-5377.2007.tb01291.x
Published online: 17 September 2007
Download PDF
Share: Share on Blue Sky Share on Facebook Share on LinkedIn Share by email

To the Editor: The Guidelines for the management of acute coronary syndromes 20061 state: “Enoxaparin may be used in conjunction with fibrin-specific fibrinolytic agents in patients under the age of 75 years, provided they do not have significant renal dysfunction. An intravenous bolus dose of 30 mg followed by a 1 mg/kg subcutaneous injection every 12 hours in combination with tenecteplase is the most comprehensively studied therapy.”1

In Australia, enoxaparin is not licensed for intravenous use (Tony Hall, Team Leader, High Risk Medications and Systems, and Christine Maclean, Associate Director, Safe Medication Practice Unit, Queensland Health, personal communication) and there is no recommendation for the intravenous use of enoxaparin in the drug product information.2 Are the authors recommending “off-label” use of intravenous enoxaparin, or do they wish to modify the guidelines to reflect what the management should be if clinicians are unable to use intravenous enoxaparin?

Authors

  • Mark Little1
  • Chris Johnstone1
  • 1. Emergency Department, Caboolture Hospital, Caboolture, QLD.

Correspondence: mark_little@health.qld.gov.au

References

View this article on Wiley Online Library

More like this

View more